Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study.
Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, Bernier C, Le Moigne M, Passeron T, Boukari F, Garnier M, Jachiet M, Tetart F, Seneschal J, Toussaint C, Mahé E, Leleu C, Regnault MM, Pasteur J, Nosbaum A, Badaoui A, Fougerousse AC, Pralong P, Viguier M, Droitcourt C, Abasq C, Mallet S, Raison-Peyron N, Staumont-Sallé D, Hubiche T; FRench Atopic DErmatitis Network (FRADEN) from the Groupe de Recherche sur l’Eczéma Atopique (GREAT) Research Group.
Beyrouti A, et al. Among authors: toussaint c.
J Allergy Clin Immunol Pract. 2024 Dec 11:S2213-2198(24)01241-8. doi: 10.1016/j.jaip.2024.12.001. Online ahead of print.
J Allergy Clin Immunol Pract. 2024.
PMID: 39672377